ROS1 and non-small cell lung carcinoma: In an ongoing phase 1 study, NSCLC and neuroblastoma patients with ALK mutations, NSCLC patients with ROS1 mutations, and colorectal cancer patients with TRK-A mutations achieved a response without dose-limiting toxicity (NCT02097810) [72].